UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 13, 2024
(Exact Name of Registrant Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code: 215 -619-3200
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02. |
Results of Operations and Financial Condition.
|
On November 13, 2024, STRATA Skin Sciences, Inc. (the “Company”) issued
a press release announcing its results of operations for the first fiscal quarter ended June 30, 2024. The full text of such press
release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On November 13, 2024, Strata Skin Sciences, Inc. (the “Company”) designated its Vice President Finance, John Gillings, as its
principal financial officer and principal accounting officer.
Mr. Gillings, age 49, has been our Vice President Finance since this past August. He previously acted as a consultant in various capacities in
connection with MedTech fundraising and diligence. From 2019 to 2023, Mr. Gillings served as Vice President of Accelmed, a private equity investment firm focused on medical device companies. From 2018 to 2019 he served as Head of Investor Relations
at Apollo Endosurgery, a MedTech company, and before that, from 2012 to 2018, he served as Vice President Equity Research with JMP Securities. Mr. Gillings holds a Masters in Finance from the London Business School, and a B.A. and M.A. in Accounting
from the University of Utah. There are no changes to Mr. Gillings’ compensation as a result of this designation, and there are no transactions or proposed transactions to which the Company is a party or intended to be a party in which Mr. Gillings
has or will have a material interest subject to disclosure under Item 404(a) of Regulation S-K. Mr. Gillings does not have any family relationships with any current director, executive officer, or person nominated to become a director or executive
officer, of the Company.
| Item 7.01. |
Regulation FD Disclosure.
|
On November 13, 2024, STRATA Skin Sciences, Inc. (the “Company”) issued a press release announcing its results of operations for the
first fiscal quarter ended June 30, 2024. The full text of such press release is furnished as Exhibit 99.1 to this report.
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits.
|
The following press release is furnished as an exhibit to this Current Report on Form 8-K pursuant to Item 2.02 and shall not be
deemed to be “filed”:
|
|
99.1 |
Press Release dated November 13, 2024 issued by STRATA Skin Sciences, Inc. |
|
|
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
STRATA SKIN SCIENCES, INC.
|
|||
|
Date: November 13, 2024
|
By:
|
/s/ John Gillings
|
|
|
Chief Accounting Officer
|
|||